Hepatocellular carcinoma in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding hepatocellular carcinoma

Hepatocellular carcinoma is a primary cancer of liver cells. A single large liver mass in a dog can behave very differently from multifocal or diffuse liver cancer, and some solitary tumors can be treated very successfully with surgery. The first questions are how much liver is involved, whether major vessels are affected and whether the mass can be removed safely.

What does the prognosis look like?

If there is one removable liver mass and no spread, surgery can be genuinely worthwhile. In a classic study, the typical survival time exceeded 4 years in dogs selected for liver-lobe removal and was about 9 months in a small nonsurgical group. The groups were not equivalent, and surgery did not start the disease clock. The useful message is that a large solitary removable mass is not automatically hopeless, while multifocal, diffuse or unresectable cancer is a very different situation.

What matters next

The key question is whether this is one removable liver mass or more widespread liver disease. A large solitary mass can still be surgically treatable, so size alone should not make the decision. Imaging should show its relationship to major vessels and other liver lobes before the outlook is judged.

Where are you now?

There is one apparently resectable liver mass

Ask for surgical review of the mass in relation to major vessels and central liver structures. A solitary resectable massive HCC can have a very different outlook from multifocal or diffuse liver cancer.

Liver surgery has already been done

Review final pathology, margins, and whether staging showed additional lesions. A completely resected solitary massive hepatocellular carcinoma can behave very differently from multifocal disease and does not automatically require chemotherapy.

There are multiple or diffuse liver lesions

Do not apply favorable surgery statistics from solitary massive hepatocellular carcinoma. Confirm the diagnosis, liver function, and distribution of disease before deciding whether biopsy, systemic treatment, or supportive care is useful.

The mass cannot be removed

Ask why it is unresectable: vascular involvement, central location, multifocal disease, metastasis, or overall health. Those reasons lead to different realistic alternatives.

If you are waiting for oncology

The most important question is whether this is a solitary resectable liver mass or multifocal/diffuse disease. High-quality imaging and surgical review are usually more useful than treating all liver tumors as one category.

Questions to ask your oncologist

Is this a solitary massive HCC, or is disease multifocal or diffuse?
Is the mass resectable given its vessels and location?
If surgery is not feasible, what exactly makes it unresectable and what alternatives follow from that?

How the diagnosis may appear in the record

Ask whether imaging and pathology describe a solitary massive hepatocellular carcinoma or nodular, multifocal, diffuse, or invasive liver disease. Those patterns have very different surgical possibilities. The report should also clarify involved lobes, vascular invasion, margins after surgery, and visible spread.

Changes to watch for at home

Report reduced appetite, vomiting, abdominal swelling or pain, weakness, weight loss, jaundice, or pale gums. Collapse, marked abdominal distension, severe weakness, or suspected internal bleeding is urgent. Large tumors can cause mechanical or bleeding problems even before liver function fails.

How it is usually treated

A solitary resectable hepatocellular carcinoma is usually treated with liver lobectomy, which can provide excellent local control. Multifocal, diffuse, invasive or metastatic disease requires a different plan and may lead to discussion of systemic treatment, interventional techniques or clinical trials.

What can affect treatment choices

Whether the cancer is one removable mass or multifocal or diffuse disease is the main dividing line. Its relationship to major vessels, liver function, metastasis and surgical fitness also matter.

Tests that may matter

Abdominal ultrasound or CT helps determine whether the tumor is solitary and surgically removable and shows its relationship to major vessels. Blood chemistry helps assess liver function and surgical risk. Cytology can be inconclusive, so biopsy or surgical pathology may be needed for a definitive diagnosis.

Treatment options available now

5 options currently in our catalog.

Check eligibility

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

H-FIRE tumor ablation before surgery for canine liver cancer

Purdue University Veterinary Hospital — Werling Comparative Oncology Research Center · USA

Location

Purdue University Veterinary Hospital, 625 Harrison St, West Lafayette, IN 47907

Study details

Currently enrolling

What is being offered: High-frequency irreversible electroporation (H-FIRE) followed 5–7 days later by surgical liver-tumor resection

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Liver tumor; Resectable; Planned surgical resection; Anesthesia candidate

May not qualify if: Coagulation disorder; Severe systemic illness; Owner declines post hfire surgery

Costs / coverage: 🟡 Partially funded — H-FIRE, post-treatment CT and study rechecks are covered, with a $2,000 credit toward surgical resection. Owners pay remaining surgery costs, complications unrelated to H-FIRE and unrelated care.

Contact: Purdue Tumor Ablation Lab — TumorAblation@purdue.edu; Purdue Veterinary Hospital Referrals — 765-494-1107

Official study / enrollment information →

Transarterial embolization or chemoembolization for non-resectable canine liver tumors

UC Davis Veterinary Medical Teaching Hospital · USA

Location

UC Davis Veterinary Medical Teaching Hospital, 1 Garrod Dr, Davis, CA 95616

Study details

Active - Recruiting

What is being offered: Transarterial embolization (TAE) or transarterial chemoembolization (TACE), with CT-based response assessment about four weeks later

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Nonresectable or high surgical risk; Anesthesia eligible

May not qualify if: Significant other organ disease

Costs / coverage: 🟡 Partially funded. The study covers study exams, diagnostic tests and CT scans; owners pay for the TAE/TACE procedure and treatment of procedure-related complications.

Contact: Dr. Bill Culp — wculp@ucdavis.edu; 530-752-1393

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →